Discover
Great EU-funded Innovations

Innovation

Integrated Computational Heart Model for Virtual Clinical Trials

Market Maturity

Tech Ready: More about market maturity categories

Innovation topic

Health & Care

Date of analysis

Innovation Radar's analysis of this innovation is based on data collected on 27/07/2019

Go to market needs

Needs that, if addressed, can increase the chances this innovation gets to (or closer to) the market incude:

  • Prepare for Market entry
  • Secure capital
  • Scale-up market opportunities
  • Market Creation Potential

    This innovation was assessed by the JRC’s Market Creation Potential indicator framework as having a “High” level of Market Creation Potential. Only innovations that are showing multiple signals of market creation potential are assigned a value under this indicator system.

    Project

    This innovation was developed under the Horizon 2020 project SILICOFCM. Details of this project are provided below:

    Project acronym: SILICOFCM

    Project Title: In Silico trials for drug tracing the effects of sarcomeric protein mutations leading to familial cardiomyopathy

    Project description: According to the 2014 European Society of Cardiology Guidelines, cardiomyopathies are defined as structural and functional abnormalities of the ventricular myocardium that are unexplained by flow limiting coronary artery disease or abnormal loading conditions. There are four major classifications of cardiomyopathy: hypertrophic (HCM), dilated (DCM), restrictive (RCM), and arrhythmogenic right ventricular (ARVC). Familial cardiomyopathies (FCM) are most commonly diagnosed, or progress of the disease is monitored, through in vivo imaging, with either echocardiography or, increasingly, cardiac magnetic resonance imaging (MRI). The treatment of symptoms of FCM by established therapies could only in part improve the outcome, but novel therapies need to be developed to affect the disease process and time course more fundamentally. SILICOFCM project will develop in silico computational cloud platform which will integrate from stopped-flow molecular kinetic assays to magnetic resonance imaging of the whole heart, bioinformatics and image processing tools with state of the art computer models with the aim to reduce animal and clinical studies for a new drug development and optimized clinical therapy of FCM. The developed system will be distributed on the cloud platforms in order to achieve efficient data storage and high-performance computing, that can offer end users results in reasonably short time. Academic technical partners IIT, UOI, UL and BSC will be responsible for developing and integration of in silico cloud computational platform with multi-scale cardiac muscle modelling which include experiments on protein mutation in vitro from UNIKENT, UNIFI and UW. Bioinformatics tools will be integrated by US company SBG. Clinical partners UNEW, ICVDV, UPMC and UHREG will do retrospective and prospective studies. SME partner R-Tech will be in charge of regulatory issues and reports and BIOIRC will do the exploitation of the project.

    Project end date: 30/11/2021

    More info:

    • Read more about this project on CORDIS (find names of contact persons and their phone numbers on the CORDIS page)

    • Details of this project on the Horizon 2020 dashboard

    Key Innovator(s)

    Steinbeis Advanced Risk Technologies GmbH

    STUTTGART, DE

    Small or Medium Enterprise

    UNIVERZA V LJUBLJANI

    LJUBLJANA, SI

    Higher Education Institute / Research Centre